4th Quarter - Report

BIOGEN for BIOGEN

Firm
Client
Income
—
Expenses
$700,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number

LobbyistCovered position, as disclosed
JONATHAN CAUSEY —
JOHN RAYMOND GIBSON —
TYLER HANSON —
DANIEL HARDER —
ALI LAKHANI —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: S. 1214 (118th), S. 3558 (118th)

Medicare/Medicaid MMM

Issues related to the 340B program reforms

LobbyistCovered position, as disclosed
JONATHAN CAUSEY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Pharmacy PHA

Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act

LobbyistCovered position, as disclosed
JONATHAN CAUSEY —
DANIEL HARDER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5539 (118th), S. 1967 (118th), H.R. 830 (118th), S. 1542 (118th)

Taxation/Internal Revenue Code TAX

Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) American Innovations and Jobs Act issues related to OECD negotiations on the taxation of global income

LobbyistCovered position, as disclosed
DANIEL HARDER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Copyright/Patent/Trademark CPT

Support stronger IP and exclusivity protections and enforcement in foreign markets Biopharmaceutical innovation and patent policy Bayh-Dole March-in rights, Patent thicket, and AI policy issues

LobbyistCovered position, as disclosed
JONATHAN CAUSEY —
DANIEL HARDER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Manufacturing MAN

General issues related to the manufacturing workforce

LobbyistCovered position, as disclosed
DANIEL HARDER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.